Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Eledon Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

AUSTIN, TEXAS & IRVINE, CALIF.--(BUSINESS WIRE)--NATERA, INC. (NASDAQ: NTRA), A GLOBAL LEADER IN CELL-FREE DNA AND PRECISION MEDICINE, AND ELEDON PHARMACEUTICALS, INC. (NASDAQ: ELDN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING IMMUNE-MODULATING THERAPIES FOR THE MANAGEMENT AND TREATMENT OF LIFE-THREATENING CONDITIONS, TODAY ANNOUNCED A STRATEGIC PARTNERSHIP TO INCORPORATE NATERA'S PROSPERA KIDNEY TRANSPLANT ASSESSMENT TEST INTO ELEDON'S PLANNED PHASE 3 CLINICAL TRIAL OF TEGOPRUBART, AN IN.

NATERA AND ELEDON ANNOUNCE STRATEGIC PARTNERSHIP FOR PROSPERA MONITORING IN PLANNED PHASE 3 KIDNEY TRANSPLANT TRIAL

ELEDON PRESENTS LONG-TERM PHASE 2 BESTOW RESULTS AT ATC SHOWING SUSTAINED HIGHER KIDNEY FUNCTION AND IMPROVED PATIENT-REPORTED OUTCOMES WITH TEGOPRUBART

ELEDON PRESENTS LONG-TERM EXTENSION PHASE 2 BESTOW RESULTS AT AMERICAN TRANSPLANT CONGRESS SHOWING SUSTAINED HIGHER KIDNEY FUNCTION AND IMPROVED PATIENT-REPORTED OUTCOMES WITH TEGOPRUBART COMPARED WITH TACROLIMUS

 ALL 12 PATIENTS IN STUDY (100%) ACHIEVED INSULIN INDEPENDENCE, PRODUCING THEIR OWN INSULIN AND NO LONGER REQUIRING EXOGENOUS INSULIN THERAPY TO MANAGE THEIR T1D  ALL 12 PATIENTS ALSO ACHIEVED AN HBA1C BELOW 6.5%, WITH A MEAN MOST RECENT HBA1C OF APPROXIMATELY 5.4%, REPRESENTING AN APPROXIMATELY 2.6% AVERAGE IMPROVEMENT IN HBA1C FROM BASELINE  NO SEVERE HYPOGLYCEMIC EPISODES WERE REPORTED POST-TRANSPLANT, COMPARED WITH A HISTORY OF RECURRENT SEVERE HYPOGLYCEMIC EVENTS PRIOR TO TRANSPLANTATION IN ALL ENROLLED PATIENTS IRVINE, CALIF., JUNE 08, 2026 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC.(ELEDON) (NASDAQ: ELDN) TODAY ANNOUNCED UPDATED RESULTS FROM AN INVESTIGATOR-INITIATED TRIAL EVALUATING TEGOPRUBART, ITS INVESTIGATIONAL ANTI-CD40L ANTIBODY, AS PART OF A CALCINEURIN INHIBITOR-FREE IMMUNOSUPPRESSION REGIMEN IN PATIENTS WITH TYPE 1 DIABETES UNDERGOING ALLOGENEIC ISLET CELL TRANSPLANTATION AT THE UNIVERSITY OF CHICAGO MEDICINE TRANSPLANT INSTITUTE.

ELEDON ANNOUNCES UPDATED DATA FROM INVESTIGATOR-INITIATED ISLET TRANSPLANT TRIAL OF TEGOPRUBART IN PATIENTS WITH TYPE 1 DIABETES (T1D) AT UCHICAGO MEDICINE

ELEDON ANNOUNCES PRESENTATION OF UPDATED DATA FROM INVESTIGATOR-INITIATED ISLET TRANSPLANT TRIAL OF TEGOPRUBART IN PATIENTS WITH TYPE 1 DIABETES AT ADA

ELEDON ANNOUNCES PRESENTATION OF UPDATED DATA FROM INVESTIGATOR-INITIATED ISLET TRANSPLANT TRIAL OF TEGOPRUBART IN PATIENTS WITH TYPE 1 DIABETES AT AMERICAN DIABETES ASSOCIATION (ADA) 2026 SCIENTIFIC SESSIONS

IRVINE, CALIF., MAY 20, 2026 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT NEW CLINICAL DATA FROM ITS TEGOPRUBART PROGRAM IN PATIENTS UNDERGOING KIDNEY TRANSPLANTATION IN AN ORAL AND A POSTER PRESENTATION AT THE AMERICAN TRANSPLANT CONGRESS (ATC) TAKING PLACE IN BOSTON, MA FROM JUNE 20-24, 2026.

ELEDON PHARMACEUTICALS TO PRESENT NEW LONG-TERM DATA FROM PHASE 2 BESTOW TRIAL OF TEGOPRUBART FOR THE PREVENTION OF REJECTION IN KIDNEY TRANSPLANTATION AT AMERICAN TRANSPLANT CONGRESS

100% INSULIN INDEPENDENCE ACHIEVED IN 10 PATIENTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART FOLLOWING ISLET TRANSPLANTATION IN UCHICAGO MEDICINE-LED STUDY FDA ORPHAN DRUG DESIGNATION GRANTED TO TEGOPRUBART FOR THE PREVENTION OF ALLOGRAFT REJECTION IN LIVER TRANSPLANTATION CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $111.1 MILLION AS OF MARCH 31, 2026 IRVINE, CALIF., MAY 13, 2026 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY REPORTED ITS FIRST QUARTER 2026 OPERATING AND FINANCIAL RESULTS AND PROVIDED RECENT BUSINESS HIGHLIGHTS.

ELEDON PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

ZURICH, SWITZERLAND, APRIL 20, 2026 (GLOBE NEWSWIRE) -- NEWCELX LTD. (NASDAQ: NCEL), NEWCELX LTD. (NASDAQ: NCEL), A CLINICAL-STAGE REGENERATIVE MEDICINE COMPANY DEVELOPING STEM-CELL-DERIVED THERAPIES, TODAY ANNOUNCED THE RELEASE OF AN UPDATED CORPORATE PRESENTATION THAT INCLUDES THE COMPANY'S STRATEGIC COLLABORATION WITH ELEDON PHARMACEUTICALS (NASDAQ: ELDN) AND HIGHLIGHTS THE ADVANCEMENT OF ITS FLAGSHIP TYPE 1 DIABETES PROGRAM, NCEL-101, AS A CENTRAL PILLAR OF THE COMPANY'S DEVELOPMENT STRATEGY.

NEWCELX UPDATES CORPORATE PRESENTATION TO HIGHLIGHT TYPE 1 DIABETES FLAGSHIP PROGRAM FOLLOWING STRATEGIC COLLABORATION WITH ELEDON PHARMACEUTICALS AHEAD OF SWISS BIOTECH CONFERENCE

REPORTED UPDATED RESULTS FROM 12 PATIENTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART FOLLOWING ISLET TRANSPLANTATION IN UCHICAGO MEDICINE-LED STUDY PRESENTED 24-MONTH FOLLOW-UP DATA FROM PHASE 1B LONG-TERM EXTENSION STUDY WHICH CONTINUES TO SUPPORT THE FAVORABLE SAFETY AND TOLERABILITY PROFILE OF TEGOPRUBART TEGOPRUBART GRANTED ORPHAN DRUG DESIGNATION BY THE FDA FOR THE PREVENTION OF ALLOGRAFT REJECTION IN LIVER TRANSPLANTATION IRVINE, CALIF., MARCH 19, 2026 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY REPORTED ITS FOURTH QUARTER AND FULL YEAR 2025 OPERATING AND FINANCIAL RESULTS AND REVIEWED RECENT BUSINESS HIGHLIGHTS.

ELEDON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2025 OPERATING AND FINANCIAL RESULTS

IRVINE, CALIF., MARCH 10, 2026 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC.(ELEDON) (NASDAQ: ELDN) TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED ORPHAN DRUG DESIGNATION TO TEGOPRUBART FOR THE PREVENTION OF ALLOGRAFT REJECTION IN LIVER TRANSPLANTATION.

ELEDON PHARMACEUTICALS ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO TEGOPRUBART FOR THE PREVENTION OF ALLOGRAFT REJECTION IN LIVER TRANSPLANTATION

COLLABORATION INTEGRATES STEM-CELL-DERIVED ISLETS WITH TARGETED IMMUNE MODULATION ZURICH, SWITZERLAND, MARCH 9, 2026 /PRNEWSWIRE/ -- NEWCELX LTD. ("NEWCELX") (NASDAQ: NCEL), A CLINICAL-STAGE COMPANY ADVANCING STEM-CELL-DERIVED THERAPIES FOR TYPE 1 DIABETES, TODAY ANNOUNCED A COLLABORATIVE RESEARCH AGREEMENT WITH ELEDON PHARMACEUTICALS, INC. ("ELEDON") (NASDAQ: ELDN), A CLINICAL-STAGE IMMUNOLOGY COMPANY WITH A FOCUS ON TRANSPLANT MEDICINE.

Eledon Pharmaceuticals, Inc.

ELDN

Price

Financial Reports

No items found.

Press Releases

Eledon Pharmaceuticals, Inc.

ELDN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ELDN